375 related articles for article (PubMed ID: 24715128)
1. The newer direct oral anticoagulants: a practical guide.
Thachil J
Clin Med (Lond); 2014 Apr; 14(2):165-75. PubMed ID: 24715128
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
[TBL] [Abstract][Full Text] [Related]
3. Target-specific oral anticoagulants: practice issues for the clinician.
Plitt A; Giugliano RP
Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
[TBL] [Abstract][Full Text] [Related]
4. New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Bhimani AA; Hong M
Rev Recent Clin Trials; 2013 Jun; 8(2):78-85. PubMed ID: 23859143
[TBL] [Abstract][Full Text] [Related]
5. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Douketis J; Bell AD; Eikelboom J; Liew A
Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
[TBL] [Abstract][Full Text] [Related]
6. New agents to prevent strokes in nonvalvular atrial fibrillation.
Putney D; Pratt C
Methodist Debakey Cardiovasc J; 2012; 8(3):44-6. PubMed ID: 23227289
[TBL] [Abstract][Full Text] [Related]
7. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Arepally GM; Ortel TL
Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ
Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354
[TBL] [Abstract][Full Text] [Related]
9. Novel oral anticoagulants: a review of new agents.
Wanat MA
Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899
[TBL] [Abstract][Full Text] [Related]
10. Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Kosar L; Jin M; Kamrul R; Schuster B
Can Fam Physician; 2012 Aug; 58(8):850-8. PubMed ID: 22893338
[No Abstract] [Full Text] [Related]
11. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Aguilar MI; Kuo RS; Freeman WD
Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
[TBL] [Abstract][Full Text] [Related]
12. [Improvements in oral anticoagulant therapy for atrial fibrillation].
Briongos Figuero S; García Santos-Gallego C; Badimón JJ
Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
[TBL] [Abstract][Full Text] [Related]
13. New oral anticoagulants: their role and future.
Shapiro S; Laffan M
Clin Med (Lond); 2013 Dec; 13 Suppl 6():s53-7. PubMed ID: 24298185
[TBL] [Abstract][Full Text] [Related]
14. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
15. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
16. Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Douketis J; Bell AD; Eikelboom J; Liew A
Can Fam Physician; 2014 Nov; 60(11):997-1001. PubMed ID: 25392439
[TBL] [Abstract][Full Text] [Related]
17. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Albert NM
Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
[TBL] [Abstract][Full Text] [Related]
18. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Cove CL; Hylek EM
J Am Heart Assoc; 2013 Oct; 2(5):e000136. PubMed ID: 24152980
[No Abstract] [Full Text] [Related]
19. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Harrington AR; Armstrong EP; Nolan PE; Malone DC
Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
